Bladder preservation therapy with GC radiation against invasive bladder cancer.

Bladder preservation therapy with GC radiation against invasive bladder cancer. - Bladder preservation therapy with GC radiation against invasive bladder cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006363

Enrollment

Registered

2011-09-16

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-invasive bladder cancer

Interventions

radiation combined with gemcitabine and cisplatin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have MIBC and strong desire for keeping their bladder.

Exclusion criteria

Exclusion criteria: 1 Patients who have contraindication against gemcitabine and/or cisplatin. 2 Patients who received previous irradiation to pelvis. 3 Others, patients who have unsuitable condition.

Design outcomes

Primary

Measure	Time frame
Recurrence-free survival rate	—

Secondary

Measure	Time frame
Disease-specific survival rate Overall survival rate Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactMatsumoto Hiroaki

Yamaguchi University, School of Medicine Department of Urology

hmatsumo@yamaguchi-u.ac.jp0836-22-2275

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026